07.14.15
Headquarters: Dublin, Ireland
twitter.com/Actavis
www.actavis.com
TOP SELLING DRUGS
When Actavis acquired Allergan in a mega deal for roughly $66 billion, it instantly created a top 10 global pharmaceutical company. Combined annual revenues of more than $23 billion anticipated in 2015 will push the company, which officially adopted the Allergan name, way up the charts next year.
The company said it adopted the Allergan name to ensure its corporate identity reflects the transformation of the company within the pharmaceutical industry as a leader in growth pharma. Allergan’s portfolio boasts world-renowned brands, a global generics business, a premier pharmaceutical pipeline of medicines including brands, generics, biosimilars, OTC products and devices. It is also the fourth largest distributor in the U.S., which will retain the name Anda.
During the year, Allergan initiated a rebranding campaign for the transition of its facilities, operations and commercial presence around the world. The company’s U.S. and Canadian generics business will continue to operate under the Actavis name.
twitter.com/Actavis
www.actavis.com
Headcount: | 17,000 | |
Year Established: | 2013 | |
Revenues: | $13,062 | (+51%) |
Net Loss: | ($1,268) vs ($423) | |
R&D: | $1,085 | (+76%) |
TOP SELLING DRUGS
Drug | Indication | 2014 Sales | (+/-%) |
Namenda Franchise | Alzheimer’s disease | $899 | n/a |
Delzicol/Asacol | ulcerative colitis | $564 | 276% |
Bystolic | hypertension | $293 | n/a |
Lo Loestrin Fe | contraception | $277 | 338% |
Estrace Cream | hormone cream | $258 | 325% |
When Actavis acquired Allergan in a mega deal for roughly $66 billion, it instantly created a top 10 global pharmaceutical company. Combined annual revenues of more than $23 billion anticipated in 2015 will push the company, which officially adopted the Allergan name, way up the charts next year.
The company said it adopted the Allergan name to ensure its corporate identity reflects the transformation of the company within the pharmaceutical industry as a leader in growth pharma. Allergan’s portfolio boasts world-renowned brands, a global generics business, a premier pharmaceutical pipeline of medicines including brands, generics, biosimilars, OTC products and devices. It is also the fourth largest distributor in the U.S., which will retain the name Anda.
During the year, Allergan initiated a rebranding campaign for the transition of its facilities, operations and commercial presence around the world. The company’s U.S. and Canadian generics business will continue to operate under the Actavis name.
Having completed the buy-out of Allergan in April, the combined companies will now boast revenues of somewhere in the region of $23 billion, which is massive growth. Having come from what now seems a tiddly Watson Pharmaceuticals, the Irish big-lad is no stranger to acquisitions and mergers with a string of them attached to its history—but this was a biggy! And illustrating just how important this is to the company, it has ceased trading as Actavis and will be known as Allergan from here on in. But it doesn’t look like the company is going to stop there. Senior management strategy says that it’s a lot easier to buy drug candidates that look likely to go somewhere, saving them a lot of the elbow work, time, effort and money of early stage development that has a high chance of going down the drain. So, 2015 may hold other strategic acquisitions and this time next year Allergan doesn’t plan on being in the same place. Financial results from 1Q15 have rocketed compared with last year and it hopes there will be more to come. But don’t worry, Actavis hasn’t disappeared completely, the name will stay on in the U.S. and Canada flying their generics flag. —Adele Graham-King |